STI-1386

AXP000135.1 · Oncolytic virus

Platform
HSV-1 (second-generation oncolytic, immune-payload armed)
Originator
Virttu Biologics / Sorrento Therapeutics
Sponsor
Sorrento Therapeutics

Names

NameTypeSource
STI-1386preferred name, codecurator, ncit
Seprehveccodencit
Oncolytic HSV-1 STI-1386synonymncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
conditionally replicating
Modifications
second-generation oncolytic HSV-1 backbone; deletions not specified in NCIt
Transgenes
anti-PD-1 scFv-Fc, TGFBR2 decoy, IL12A, IL12B
Route
intravenous
Source
evidence

Cross-references

NCI Thesaurus
C187651

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05361954Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid TumorsNot yet recruitingPhase 12023-082026-1036Cancer; Cancer of Pancreas; Hepatic Metastasis; Sarcoma; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Notes

Second-generation oncolytic HSV-1 expressing an anti-PD-1 scFv-Fc, a TGF-beta receptor II decoy and IL-12 (NCIt C187651); development name Seprehvec, after Sorrento/Virttu's first-generation Seprehvir (HSV1716, AXP000073). Phase 1b NCT05361954 was registered in 2022 but still shows 'not yet recruiting'; Sorrento filed for bankruptcy in 2023, so whether any patient was dosed is unverified.

How to cite

STI-1386 (AXP000135.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000135.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.